ACD/Labs has released version 25.4 of Katalyst D2D, extending the industry-leading workflow digitalisation software beyond its original high throughput experimentation applications to support process scale-up and material characterisation in pharmaceutical development. The enhanced platform enables pharmaceutical project teams to accelerate the design-make-test-analyse cycle from discovery through to clinical trials.

Comprehensive integration with laboratory systems

The software distinguishes itself through integration with third-party informatics systems, laboratory automation hardware, and analytical instrument data. Katalyst D2D manages experimental data across workflows, reducing transcription errors whilst providing contextual information for experimental results.

The platform generates machine-ready instruction lists for robotics platforms and manual procedures, automates analytical data processing from LC/MS, LC/UV, NMR, XRPD, thermal analysis, and microscopy systems, and imports data from diverse laboratory instruments. Version 25.4 adds support for in-situ sampling data from laboratory reactors and instruments including IR/Raman, TGA, DSC, and Karl Fischer titrators.

“This release of Katalyst D2D is the direct result of close collaboration with key opinion leaders in the pharmaceutical industry,” said Andrew Anderson, Vice President Innovation & Informatics Strategy at ACD/Labs. “By listening to the digital aspirations of project teams and scientific leaders, we’ve expanded the capabilities of Katalyst to address the most pressing challenges in pharmaceutical development.”

Structured data for advanced analytics

Scientists can design chemistry, manufacturing and controls studies manually or integrate third-party artificial intelligence tools for design of experiments. The structured, contextualised data assembled by Katalyst enables cross-experiment analysis and supports advanced data science applications including artificial intelligence and machine learning workflows.

“Scientists want to leverage as much automation as possible to increase the pace of experimentation,” said Alex Waked, Solution Area Manager, Katalyst D2D. “This latest Katalyst release supports a wide variety of important experiment modalities, and, with different project teams now able to work in the same software, scientists are empowered to share data and collaborate more easily.”

The enhanced functionality supports synthetic route optimisation and process scale-up studies across pharmaceutical development workflows, enabling organisations to validate manufacturing processes more rapidly.

For more information, visit: https://www.acdlabs.com/katalystd2d

Digital issue: Please click here for more information